BPG is committed to discovery and dissemination of knowledge
Articles in Press
12/8/2025 9:28:54 AM | Browse: 17 | Download: 0
| Category |
Orthopedics |
| Manuscript Type |
Case Control Study |
| Article Title |
Risk factors for thoracic-osteoporotic thoracic vertebral compression fractures during the normalized prevention and control period of COVID-19
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yi-Fan Li, Chen-Qiong Wu, Yang Long, Qi-Feng Yu, Wei Xu, Jian-Jie Zhao, Xiang-Yang Zhang and Zhi-Kun Li |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Shanghai Municipal Health Commission |
2022YQ006 |
| Doctoral Innovation Base Project in Changning District |
RCJD2022S02 |
|
| Corresponding Author |
Zhi-Kun Li, MD, PhD, Department of Spine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, No. 1111 Xianxia Road, Shanghai 200080, China. lizhikun@shsmu.edu.cn |
| Key Words |
COVID-19; Normalized prevention and control; Osteoporotic vertebral compression fracture; Risk factor; Cough |
| Core Tip |
During the normalized prevention and control period of coronavirus disease 2019, compared with cases in the same period, cough is the main cause of osteoporotic vertebral compression fracture (OVCF), and most fractures are thoracic fractures. After percutaneous vertebroplasty treatment, the improvement of pain and function in patients is not significantly different from that in the same period. Regression analysis shows that cause of fracture, nucleic acid test result, body mass index, and bone mineral density are independent risk factors for thoracic OVCF. For elderly COVID-19-positive patients with recurrent cough, timely and active treatment of lung diseases, aggressive anti-osteoporosis therapy, and wearing a thoracic brace for protection are effective measures to prevent thoracic OVCF. |
| Citation |
Li YF, Wu CQ, Long Y, Yu QF, Xu W, Zhao JJ, Zhang XY, Li ZK. Risk factors for thoracic-osteoporotic thoracic vertebral compression fractures during the normalized prevention and control period of COVID-19. World J Orthop 2025; In press |
 |
Received |
|
2025-10-11 08:54 |
 |
Peer-Review Started |
|
2025-10-11 08:54 |
 |
First Decision by Editorial Office Director |
|
2025-10-23 08:24 |
 |
Return for Revision |
|
2025-10-23 08:24 |
 |
Revised |
|
2025-10-30 14:49 |
 |
Publication Fee Transferred |
|
2025-11-01 13:37 |
 |
Second Decision by Editor |
|
2025-12-08 02:38 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2025-12-08 09:28 |
 |
Articles in Press |
|
2025-12-08 09:28 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
|
| ISSN |
2218-5836 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345